ScripPfizer stands to expand the addressable market for its hemophilia A and B drug Hympavzi (marstacimab-hncq) with Phase III data showing it is effective in patients with clotting factor inhibitors along
ScripSangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data suppo
ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its